# Radiopharm Theranostics Limited (RADX)

> Source: Nexqual · https://nexqual.com/RADX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Radiopharm Theranostics Limited (RADX), nexqual.com/RADX" · informational, not investment advice.

**Price:** USD 1.08 (-3.57% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.12 · day 1.01–1.15 · 52w 1–16.25 · market cap $15.8M · NCM

## Key facts
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 16.95 (range 12.41–29.94).
- Total return with dividends: 1Y -84.8% vs S&P 500 +18.1%; 5Y -94.3% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 16.95 (low 12.41, high 29.94).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-12-02) |
|---|---|---|
| Total return | -84.8% | -94.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -84.9% | -78.4% |
| Volatility (annualized) | 129.8% | 110.6% |
| Max drawdown | -89.8% (Dec 2025→Oct 2026) | -94.3% (Dec 2024→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/RADX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt